Related Experiment Video
Updated: Jul 13, 2026

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
Published on: January 20, 2023
Heat-shock protein-peptide complex-96 for the treatment of cancer
1The Methodist Hospital Research Institute, Genitourinary Oncology Program, Houston, Texas, USA. ramato@tmh.tmc.edu
Abstract:
Heat-shock proteins (HSPs) are the most abundant and ubiquitous soluble intracellular proteins. Members of the HSP family bind peptides, including antigenic peptides generated within cells. HSPs also interact with antigen-presenting cells (APCs) through CD91 and other receptors, eliciting a cascade of events that includes representation of HSP-chaperoned peptides MHC, translocation of NF-kappaB into the nuclei, and maturation of dendritic cells. These consequences point to a key role of HSPs in fundamental immunologic phenomena such as activation of APCs, indirect presentation (or crosspriming) of antigenic peptides, and chaperoning of peptides during antigen presentation. The properties of HSPs also allow them to be used for immunotherapy of cancers and infections in novel ways. This paper reviews the development and clinical trial progress of vitespen, an HSP peptide complex vaccine based on tumor-derived glycoprotein 96.
Insights
Heat-shock proteins (HSPs) are crucial for immune responses, binding peptides and activating antigen-presenting cells. Vitespen, an HSP-based vaccine, shows promise for cancer and infection immunotherapy.
Area of Science:
- Immunology
- Molecular Biology
- Oncology
Background:
- Heat-shock proteins (HSPs) are abundant intracellular proteins involved in cellular stress responses.
- HSPs bind peptides, including antigenic peptides, and interact with antigen-presenting cells (APCs) via receptors like CD91.
- These interactions initiate immune signaling pathways, such as NF-kappaB translocation and dendritic cell maturation.
Purpose of the Study:
- To review the role of HSPs in fundamental immunologic phenomena.
- To discuss the development and clinical trial progress of vitespen, an HSP-based vaccine.
- To highlight the potential of HSPs in cancer and infection immunotherapy.
Main Methods:
- Review of existing literature on HSPs and their immunologic functions.
- Analysis of data from clinical trials involving vitespen.
- Examination of the mechanism of action of HSP peptide complex vaccines.
Main Results:
- HSPs play a key role in APC activation and cross-priming of antigenic peptides.
- HSPs facilitate peptide chaperoning during antigen presentation.
- Vitespen, a vaccine derived from tumor glycoprotein 96, is under clinical investigation.
Conclusions:
- HSPs are critical mediators of innate and adaptive immunity.
- HSP-based therapies, like vitespen, represent a promising strategy for cancer and infectious disease immunotherapy.
- Further research and clinical trials are essential to fully realize the therapeutic potential of HSPs.
Related Concept Videos
Bacterial Protein Maturation
Molecular Chaperones and Protein Folding
The...
Other Stress Responses in Bacteria

